Amphastar Pharmaceuticals (NASDAQ:AMPH) posted its earnings results on Thursday. The company reported $0.12 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.11 by $0.01, Briefing.com reports. Amphastar Pharmaceuticals had a negative net margin of 3.39% and a positive return on equity of 2.15%. The company had revenue of $75.54 million during the quarter, compared to analysts’ expectations of $76.84 million. During the same quarter in the previous year, the company posted $0.07 earnings per share. Amphastar Pharmaceuticals’s quarterly revenue was up 30.5% compared to the same quarter last year.
Shares of Amphastar Pharmaceuticals stock traded up $0.88 during midday trading on Friday, reaching $21.59. The company had a trading volume of 735,306 shares, compared to its average volume of 117,925. The company has a debt-to-equity ratio of 0.11, a current ratio of 1.94 and a quick ratio of 1.24. The firm has a market cap of $890.44 million, a P/E ratio of 56.82, a P/E/G ratio of 8.77 and a beta of 1.38. Amphastar Pharmaceuticals has a 1-year low of $14.40 and a 1-year high of $21.65.
In related news, Director Richard K. Prins sold 10,000 shares of the firm’s stock in a transaction that occurred on Tuesday, August 14th. The shares were sold at an average price of $17.82, for a total value of $178,200.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, General Counsel Jason B. Shandell sold 16,095 shares of the firm’s stock in a transaction that occurred on Friday, November 9th. The shares were sold at an average price of $20.99, for a total transaction of $337,834.05. Following the completion of the sale, the general counsel now directly owns 204,805 shares of the company’s stock, valued at approximately $4,298,856.95. The disclosure for this sale can be found here. In the last three months, insiders sold 28,502 shares of company stock valued at $558,373. 31.50% of the stock is currently owned by company insiders.
A number of research analysts have recently issued reports on AMPH shares. BidaskClub upgraded shares of Amphastar Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Thursday, August 9th. Needham & Company LLC lowered their price target on shares of Amphastar Pharmaceuticals from $24.00 to $22.00 and set a “buy” rating for the company in a report on Friday, August 10th. Zacks Investment Research lowered shares of Amphastar Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Friday, August 10th. ValuEngine raised shares of Amphastar Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Friday, August 17th. Finally, Wells Fargo & Co reissued a “buy” rating on shares of Amphastar Pharmaceuticals in a report on Friday. Two analysts have rated the stock with a hold rating, four have issued a buy rating and one has issued a strong buy rating to the stock. The company has an average rating of “Buy” and an average target price of $23.00.
TRADEMARK VIOLATION WARNING: This piece was reported by Transcript Daily and is the property of of Transcript Daily. If you are accessing this piece on another site, it was copied illegally and republished in violation of United States and international copyright and trademark law. The original version of this piece can be accessed at https://transcriptdaily.com/2018/11/10/amphastar-pharmaceuticals-amph-releases-earnings-results-beats-estimates-by-0-01-eps.html.
Amphastar Pharmaceuticals Company Profile
Amphastar Pharmaceuticals, Inc, a specialty pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States and internationally. It operates through two segments, Finished Pharmaceutical Products and Active Pharmaceutical Ingredients.
Receive News & Ratings for Amphastar Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amphastar Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.